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ABSTRACT
During normal cell metabolism, reactive oxygen species (ROS) are produced as a
byproduct of oxidative phosphorylation. ROS are utilized in the cell as a signaling molecule and
can be maintained at healthy levels by cellular antioxidants. However, when the cell experiences
oxidative stress due to environmental or genetic conditions, levels of ROS can exceed healthy
levels and inhibit necessary life functions by damaging biomolecules and cellular structures. This
loss of function can lead to physiological decline and neurodegeneration, such as in diseases like
Alzheimer’s, amyotrophic lateral sclerosis (ALS), and, potentially, Huntington’s disease. The
following experiments use the model genetic organism Drosophila melanogaster to test whether
ROS accumulation affects the symptoms of individuals infected with Huntington’s disease,
compared with individuals fed a molecular antioxidant supplement, MitoQ. We found that while
MitoQ was expected to alleviate symptoms of Huntington’s disease, individuals supplemented
with MitoQ experienced delayed development and detrimental motor function across time
independent of genotype or sex.
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INTRODUCTION
Huntington’s disease (HD) is a genetic, autosomal dominant disorder caused by a mutant
elongated polyglutamine repeat that causes cognitive and motor deterioration characterized by
chorea (abrupt, unpredictable muscle movements), memory and comprehension complications,
and, in later stages, complete deficiency of muscle movement (Novak and Tabrizi 2011). The
wild-type allele contains less than 35 repeats, while individuals experiencing symptoms of HD
will have 36+ repeats. Generally, longer repeats yield a larger phenotypic effect, although the
number of repeats only explains 50-70% of the variability in phenotypic effect, the rest of which
is due to environmental factors (Jimenez-Sanchez et al. 2017). This makes it difficult to estimate
the age of onset, strength of symptoms, and survivability of each patient. While the average age
of onset of symptoms occurs at 40 years, juvenile onset (20 years) and older onset (70 years)
have been observed (Novak and Tabrizi 2011).
Mutant HD alleles have a gain of function effect whereby the HD protein aggregates,
leading to cell toxicity and neurodegeneration. Other similar neurodegenerative disorders such as
Parkinson’s, Alzheimer’s and Amyotrophic Lateral Sclerosis (ALS) have been found to have
similar toxicity due to protein aggregation, although the causal disease genes code for completely
different proteins (Labbadia and Morimoto 2013). The aggregates are thought to cause cell death
by activating the cell cycle (Jimenez-Sanchez et al 2017). It is hypothesized that the gain of
function mutant allele in HD alters mitochondrial metabolism and can produce high levels of
reactive oxygen species (ROS). Oxidative stress caused by elevated ROS can cause injury to the
cell via DNA damage and inactivation of important enzymes due to the reactive character of
ROS. On the other hand, ROS can also act as an essential signaling molecule for maintaining
physiological functions in response to environmental changes. In the following research, we
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investigated how the mitochondria balance levels of ROS between dangerously high and critical
functional levels in a fruit fly genetic model of HD.
In humans, HD presents life-altering, chronic symptoms categorized by motor and
neurodegeneration. According to Ross and Tabrizi (2010), vital aspects of the CNS experience
prolonged deterioration and atrophy in specific regions of the brain, specifically in juvenile-onset
cases. Additionally, symptoms may include weight and muscle loss, metabolic impairments, and
weakening of endocrine function (Ross and Tabrizi 2010). While no cure exists for HD,
treatment involves symptomatic approaches. Physical and occupational therapies designed to
maximize neural and motor function can improve symptoms, but deterioration is inevitable.
Various drug therapies have also been studied to address specific symptoms that make daily life
difficult. For instance, muscle relaxers can be utilized to aid the presence of chorea but will later
exacerbate the onset of muscle weakening and decline (Novak and Tabrizi 2011).
Despite detrimental factors present in the elongated form of HD, the wild-type gene has
beneficial functions in neural development. The Huntington gene is crucial in embryo
development and control of stem cell production. When elongation of the gene occurs by
expansion of the polyglutamine repeat region, it not only induces activation of the mutant protein
to form protein aggregates, but also causes a loss of function in the wild-type advantageous gene.
The HD mutant allele thus has two effects - to increase cell toxic events and eliminating useful
function.
Huntington’s Disease occurs in approximately 4-10 individuals per every 100,0000 and
leaves many more children of non-symptomatic carriers at risk of inheriting the disease, as
elongations can expand from generation to generation (Ross and Tabrizi 2010). The average
survivability is around 15-20 years after the initial point when an individual begins showing
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symptoms. In juvenile onset cases, the progression of the disease tends to be longer and death
occurs within 10-15 years and additional symptoms such as seizures and learning disabilities
apparent in the classroom can occur (NIH 2019). Although the onset of symptoms does not occur
until generally after reproduction years (around age 40), the autosomal dominant nature of the
disease allows the predictability of inheritance to be high with the use of genetic testing (Novak
and Tabrizi 2011).
As mentioned, methods for treatment thus far have been exclusively symptomatic
although many studies attempt to address the underlying source of symptoms, although many are
unsuccessful in human patients. Cholinesterase inhibitors, which have been effectively utilized to
treat cognition decline in Alzheimer’s patients, have been unsuccessful for similar patients of
HD. An antibiotic, minocycline, functions as a caspase inhibitor and can hinder cell death. The
antibiotic was predicted to be beneficial in preventing many symptoms of HD, but was also
unsuccessful in studies on the model mouse system. Thus far, some of the more successful
methods have been gene silencing of the elongated HD allele in model organisms such as
Drosophila melanogaster (Jimenez-Sanchez et al. 2017).
More specific studies have explored the role of ROS and evading protein aggregation for
treatment of symptoms. Reducing the expression of the detrimental Huntington gene and
inhibiting protein aggregation is thought to alleviate progression of the disease (Novak and
Tabrizi 2011). In a study done by Ehrnhoefer et al., green tea polyphenol (-)-epigallocatechin-3gallate (EGCG) was used to prevent the misfolding of proteins and proved successful in
alleviating toxicity (Ehrnhoefer et al. 2006).
Currently, it remains unknown whether one specific ROS or multiple are responsible for
the damage in mitochondria that accompanies HD. The question remains whether antioxidants
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work to target one (potentially incorrect) oxidant or several oxidants and only partially alleviate
the problem caused by another more damaging molecule (Kumar and Ratan 2016). A molecular
antioxidant supplement, MitoQ, has been studied to prolong life and prevent cell apoptosis in
aging organisms. The molecule works to prevent the release of ROS from the mitochondria and
decrease cell apoptosis that is a result of oxidative stress (Kelso et al. 2001). Here we
investigated whether supplementing with MitoQ could mediate the neurodegenerative effects of
mutant HD alleles expressed in the fruit fly model of HD.
The Drosophila model for Huntington disease
Notable studies in the model organism Drosophila melanogaster have shown promising
results when targeting ROS as a source of toxicity. An enzyme called superoxide dismutase
functions to eliminate harmful ROS molecules during oxidative stress in the cells. Flies whose
genes contained three copies coding for the overexpression of the superoxide dismutase enzyme
(SOD) were observed to have a longer lifespan, less damage to proteins due to oxidative stress
(leading to lower levels of aggregated, destructive proteins), and maintained physical capabilities
into later stages of life (Orr and Sohal 1994). This study proves to be promising for future
research that works to eliminate ROS to avoid the effects of aging. A similar project studied flies
with ALS (a neurodegenerative disorder similar to HD) and successfully utilized the SOD
overexpression to observe a longer lifespan and also noted that the organisms developed
“resistance to oxidative stress,” suggesting that the flies had adapted to quench excessive ROS
and correct for the effects of oxidation (Parkes et al 1998).
Although extensive research has provided essential insight into the function of
Huntington’s Disease, there are still many gaps in information that could potentially provide the
necessary material for understanding HD and similar disorders, as well as the role of oxidative
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stress in general aging that we will attempt to determine in the following research. For instance,
it is still unclear whether ROS is a cause or effect of HD disease progression. We are unsure
whether ROS accumulates as a consequence of HD protein aggregates or whether oxidative
stress as a result of the disease progression leads to high levels of ROS that in turn cause protein
misfolding and cell death. Additionally, it is unknown whether eliminating ROS completely will
have deleterious results in the cell due to the eradication of ROS that normally functions
beneficial as a signaling molecule. Here we report the results of an experiment to test the
hypothesis that mitochondrial quenching of free radicals may ameliorate some of the
neurodegenerative consequences on Huntington disease progression in the Drosophila fly model.
Hypothesis and specific aims
We used a well-studied genetic model for human HD in the fruit fly Drosophila
melanogaster to analyze the features of ROS in diseased mitochondria and test the hypothesis
that antioxidants can be used to combat the effects of oxidative damage in symptoms of HD. Our
aims are to assess development time in HD-affected flies and non-HD individuals, with or
without dietary MitoQ supplement. I predicted that development time would be slower in HDaffected individuals, and this development delay would be ameliorated by the MitoQ antioxidant
treatment. Our second aim was to quantify the survivorship of control and diseased flies in the
presence or absence of MitoQ. My prediction was that non-diseased control flies would have the
highest rate of survival, and that HD diseased flies given MitoQ treatment would experience
greater survival than those lacking the drug treatment. My third aim was to assess the motor
function of aging flies with and without the HD disease allele. My prediction was that the HD
flies would demonstrate lower climbing heights than non-diseased individuals, due to their
characteristically weakened coordination and movement. The MitoQ treatment was predicted to
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ameliorate this deterioration, and I predicted that flies fed the dietary antioxidant would maintain
better motor skills than those lacking dietary antioxidant.

METHODS
Drosophila rearing
Two genotypes were utilized in this experiment. The control genotype expressed a short
polyglutamate allele (Htt-25) under a ubiquitous promoter and was predicted to exhibit no
symptoms of Huntington disease (HD), while the HD genotype expressed a long polyglutamate
allele (Htt-120) under a ubiquitous promoter and was predicted to exhibit symptoms of
neurodegeneration (Marsh and Thompson 2004). Each genotype was exposed to two treatments.
The first was a standard cornmeal-molasses-yeast Drosophila media on which the parent
generation mated, and offspring developed into adulthood on the same control media. The
second treatment reared offspring from egg to adult on Drosophila media containing 0.05 mM
Mito-Q. This concentration was developed from previous experiments that found larger
concentrations of Mito-Q to have toxic effects (Dalke & Montooth, unpublished results). The
Mito-Q food is designed to function as an antioxidant and prevent lipid peroxidation by ROS in
genetically compromised systems, but may also benefit healthy organisms to quench free
radicals (Magwere et al 2006). All fly cultures were maintained at 22ºC. Five replicate vials were
made for each genotype-treatment combination.
Development time
To test the effect of Mito-Q on development time, each vial of flies (five per genotypetreatment combination) was scored for both time to adult eclosion and percent survival. Methods
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from similar research on development time were modified from Buchanan et al. (2018). Thirty
female virgins of the Gal4-promoter genotype were collected and allowed to mate for
approximately 2-3 days with males from each genotype containing the UAS-HD repeat (either
Htt-25 or Htt-120). A total of five biological replicates containing 25 eggs of each genotype were
collected as third-instar larvae and placed on each type of treatment medium. Larvae were
assessed twice daily for the following days to measure number of larvae that developed into
pupae and eventually the number of males and females that reached eclosion. Each data set (time
in hours to pupation and time in hours to eclosion) was analyzed as well as the number of final
individuals that reached eclosion as a percentage of the original 25. We used analysis of variance
followed by Tukey's contrasts to assess the effects of genotype (Htt-20 control versus Htt-125
disease), treatment (control versus 0.05 mM Mito-Q) and their interaction on development.
Climbing assay and survival
Flies of each treatment were collected into 5 replicate groups of 10 individual males and
10 individual females. Every two days for 14 days, the flies were counted and recorded for
number of surviving individuals. Protocol from Feany and Bender (2000) were modified to
measure fly climbing ability. Five biological replicate vials containing the living individuals at
each of the time points were gently tapped down and flies were assessed by the height climbed
15 seconds later using video recording. The height at which 50% of the flies had climbed in
centimeters was recorded. Two technical replicates were taken of each of the 5 biological
replicates, and the flies were given 2 minutes of recovery time between technical replicates.
Technical replicates were averaged, and analysis of variance was used to test for the effects of
genotype (Htt-20 control versus Htt-125 disease), treatment (control versus 0.05 mM Mito-Q)
and their interaction on climbing ability.
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RESULTS
MitoQ delayed development time across genotypes
There was a significant difference in the amount of development time from third instar to
pupation between non-treated individuals and Mito-Q treated individuals (Table 1a) in both the
Htt-120 genotype and Htt-25 genotype. Flies receiving dietary supplement took longer to pupate
than those receiving no dietary supplement. Genotype showed no significant effect in time to
pupation. Additionally, there was some indication that the HD genotype also delayed larval
development relative to the control genotype, but only in the flies treated with MitoQ (P= 0.016).
This resulted in a significant genotype-treatment interaction (Table 1a), with MitoQ and the HD
genotype combining to delay development in larvae to pupation.
Development time to adulthood was also significantly delayed in flies that received
MitoQ treatment across genotypes. Females (Table 1b) and males (Table 1c) took longer to
eclose when fed MitoQ (Table 1b). Males with the Htt-120 disease allele under control treatment
developed to adulthood at a faster rate (P = 7.45*10-5), compared to males fed MitoQ, which
showed no effect between genotypes (P = 0.977).

Table 1A
Hours to pupation
Df Sum Sq Mean Sq F value
Pr(>F)
genotype
1
181
181.2 1.3140 0.252271
treatment
1
5200 5199.7 37.7032 1.791e-09 ***
genotype:treatment
1
1066 1066.3 7.7315 0.005651 **
Residuals
457 63026
137.9
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Table 1B
Hours to eclosion (female)
Df Sum Sq Mean Sq F value
Pr(>F)
genotype
1
197
196.9 0.6482
0.4216
treatment
1 14313 14313.1 47.1206 6.417e-11 ***
genotype:treatment
1
33
32.9 0.1082
0.7425
Residuals
225 68345
303.8
Table 1C
Hours to eclosion (male)
Df Sum Sq Mean Sq F value
Pr(>F)
genotype
1 2337.0 2337.0 17.3277 4.582e-05 ***
treatment
1 22360.1 22360.1 165.7894 < 2.2e-16 ***
genotype:treatment
1 1135.4 1135.4
8.4182 0.004109 **
Residuals
211 28457.7
134.9
MitoQ treatment was unfavorable in development time across genotypes and sexes. Time to pupation (A) was
delayed in individuals under antioxidant supplements and no difference was seen between genotypes. Time to
adulthood in females (B) and males (C) showed significant negative effect due to MitoQ supplement. However, in
males the effect of the HD allele was ameliorated by MitoQ treatment.

MitoQ had a detrimental effect on climbing activity
Although it was predicted that MitoQ would work to quench free radicals and ameliorate
the negative symptoms caused by oxidative stress in HD affected individuals, we observed that
the dietary supplement had an overall negative effect on climbing ability across all sexes and
genotypes. Initially, climbing ability was significantly negatively affected by MitoQ treatment
(Pfemales = 0.00048; Pmales = 0.018). At day 14 of the study, MitoQ treatment continued to
negatively affect climbing height compared to control treatment individuals (Pfemales = 0.00026;
Pmales = 0.029). The only effect of the Htt-120 disease allele was in females on day 14 under
MitoQ treatment (P = 0.0073), while those fed a control diet showed no difference in climbing
between genotypes. This effect was strongest in females, but also could be seen as a trend in
males (Figure 1).
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Fig. 1

Female (A) and male (B) climbing ability was statistically different between individuals on MitoQ treatment diet vs.
control diet. Day 14 shows deterioration of motor function in HD individuals, specifically under MitoQ treatment.
The effect of MitoQ was greater in males than females.
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DISCUSSION
Development time was observed to be significantly longer in individuals treated with
MitoQ antioxidant. The Drosophila model has been found to show longer development times in
organisms that have compromised systems or have been subjected to environmental stress. Our
findings show that MitoQ poses a detrimental effect on the organism, regardless of disease status
or sex. In males, however, the MitoQ treatment did seem to ameliorate the development time
effects of the Huntington disease allele. Although in control treatment flies the HD individuals
surprisingly developed to adulthood faster than the non-HD individuals, MitoQ treatment
removed any significant difference in genotypes, showing some potential in its capability as an
effective antioxidant treatment.
The detrimental effects on motor function observed in MitoQ-treated individuals,
independent of genotype, is potentially a result of the over-compensation of its antioxidant role.
By quenching free radicals unnecessarily, the cell is possibly losing essential and normal
signaling mechanisms. This is especially apparent in non-diseased flies who had significantly
decreased climbing ability when supplemented with MitoQ antioxidant. The cells may no longer
be able to respond to the normal ROS signaling that protects cells under normal physiological
conditions. Another possibility is that MitoQ is not functioning as an effective antioxidant, but is
potentially disrupting mitochondrial function, as its mode of action is by accumulation in the
mitochondrial lipid membrane bilayer.
These results do not prove to be promising for individuals affected by Huntington’s
Disease in the Drosophila model organism. Given these outcomes, we would not expect MitoQ
to be used successful in drug therapies for HD individuals, although an alternative antioxidant or
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genetic mechanism for upregulation of antioxidant enzymes may be a more promising therapy in
alleviating the symptoms of neurodegenerative disorders.
Our further research will continue to examine the molecular effect of MitoQ or other
antioxidant dietary supplements on the antioxidant capacity and ROS levels within the
mitochondria in this disease model. Assaying the organism’s antioxidant capacity is expected to
reveal the degree to which HD-affected individuals are actually experiencing oxidative stress.
Time points assessing longevity and motor function should be extended further to fully examine
the role of Huntington’s disease in aging organisms and the deterioration of motor and cognitive
function, as we observed the greatest effects only at our last time point in the experiment. Due to
the apparent detrimental effects shown by the MitoQ antioxidant, studies should continue
research for other antioxidants or various concentrations of MitoQ that will not cause detrimental
effects on naturally occurring and essential metabolic mechanisms.
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